Clinical Trial Update: PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (NCT06354140) evaluating PPIO-008 with tislelizumab and S-1 for patients with ypT+N0 esophageal squamous cell carcinoma after neoadjuva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• PPIO-008
• S-1 (tegafur/gimeracil/oteracil)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING